Proteinase-Activated Receptors (PARs) are a four-member family of G-protein coupled 26 receptors that are activated via proteolysis. PAR4 is a member of this family that is cleaved 27 and activated by the serine proteinases such as thrombin, trypsin and cathepsin-G. PAR4 is 28 expressed in a variety of tissues and cell types including the platelets, vascular smooth 29 muscle cells and neuronal cells. In studying PAR4 signaling and trafficking, we observed 30 dynamic changes in the cell membrane with spherical membrane protrusions that resemble 31 plasma membrane blebbing. Since non-apoptotic membrane blebbing is now recognized as 32 an important regulator of cell migration, cancer cell invasion, and vesicular content release 33 we sought to elucidate the signaling pathway downstream of PAR4 activation that leads to 34 such events. Using a combination of pharmacological inhibition and CRISPR/Cas9 35 mediated gene editing approaches we establish that PAR4-dependent membrane blebbing 36 occurs independently of the Gaq/11 and Gai signaling pathways and is dependent on 37 signaling via the b-arrestin-1/-2 pathway and RhoA signaling. In order to gain a more 38 comprehensive understanding of b-arrestin mediated signaling downstream of PAR4 and to 39 guide future studies, we undertook RNAseq analysis of PAR4 activated genes in control 40 cells and in cells lacking b-arrestin-1/-2. A list of differentially expressed genes was 41 generated followed by Gene Ontology (GO) and enrichment analysis revealing PAR4 42 regulation of genes involved in processes including blood coagulation and circulation, cell-43 cell adhesion, sensory perception and neuron-neuron synaptic transmission, terms that 44 relates back to known function of PAR4 and that are consistent with our finding of 45 membrane blebbing triggered by PAR4 activation. Together these studies provide further 46 mechanistic insight into PAR4 regulation of cellular function. 47 48 Proteinase activated receptors (PARs) are a four-member family of G-protein 49 coupled receptors (GPCRs). PARs are unique among GPCRs, in being activated via 50 proteolytic unmasking of a receptor activating 'tethered ligand', that interacts 51 intramolecularly with the orthosteric ligand binding pocket to trigger signaling 52 (Ramachandran et al., 2012) . PAR4, the most recently identified member of this family 53 (Xu et al., 1998), is expressed in a variety of tissues and cell types including the platelets, 54 vascular smooth muscle cells, neuronal cells, and some cancer cells. 55 Much work has been done to develop PAR1-and PAR4-targeted compounds as 56 anti-platelet agents. Both PAR1 and PAR4 are expressed in human platelets and both of 57 these receptors are activated by the coagulation cascade enzyme thrombin. Importantly 58 though, PAR1 and PAR4 appear to serve different roles in the platelet activation process 59 (Kahn et al., 1999), with PAR1 the high affinity thrombin receptor playing an initiating role 60 and the lower affinity thrombin receptor PAR4 serving to consolidate and propagate the 61 clot (Kahn et al., 1999). The PAR1 antagonist voropaxar (zontivity), while highly effective 62 in reducing cardiovascular complications, exhibited significant side effects with an elevated 63 risk for bleeding including in the brain (Morrow et al., 2012), further spurring recent efforts 64 to target PAR4. Recent work with small molecule PAR4 antagonists has supported the idea 65 that PAR4 antagonists are effective in reducing platelet rich thrombus formation in human 66 platelets ex-vivo (Wilson et al., 2017) and in rodent and non-human primate models in-vivo 67 (Wong et al., 2017). In non-human primate models, PAR4 blockade was associated with 68 low bleeding liability and had a markedly wider therapeutic window compared to the 69 commonly used antiplatelet agent clopidogrel (Wong et al., 2017).
Introduction
HEK-293 cells stably expressing wild type PAR4-YFP displayed membrane blebbing as 232 opposed to 8.2% +/-2.35 dRS-PAR4-YFP expressing cells, indicating that PAR4 triggered 233 membrane blebbing required the activation of signaling pathways that are dependent on the 234 eight-amino acid sequence in the c-tail of PAR4. Previously, we established that dRS-235 PAR4-YFP does not couple to Gaq/11 and is unable to recruit b-arrestins in response to 236 thrombin or AYPGKF-NH2 activation (Ramachandran et al., 2017) . Since this mutant 237 receptor is also unable to activate blebbing, we hypothesized that PAR4 cell shape changes 238 are Gaq/11 and or b-arrestin dependent and examined the effect of blocking these pathways 239 on bleb formation. 240 241 PAR4-mediated cell shape change is Gaq/11 and Gai independent 242 In order to determine whether PAR4 triggered blebbing is Gaq/11-dependent, we 243 treated cells with the potent and selective Gaq/11 inhibitor YM-254890 (Taniguchi et al., 244 2004) . It is well established that GPCRs couple to Gaq/11 to mobilize calcium and activate 245 protein kinase C (PKC) (Exton, 1996; Wettschureck and Offermanns, 2005) . Activated
246
PKC translocation from the cytosol to the plasma membrane can be observed to monitor 247 this process (Dale et al., 2001; Policha et al., 2006) . We employed this assay to visualize 248 the efficacy of YM-254890 in inhibiting Gaq/11 signaling through PAR4. Cells were 249 transiently transfected with PAR4-mCherry and PKCb1-GFP. PAR4 expression was 250 observed at the cell membrane and PKCb1 expression was evident in the cytoplasm in data indicates that YM-254890 functionally blocks Gaq/11 signaling as indicated by a lack 261 of PKCb1 translocation but does not block cell shape changes mediate by PAR4 activation.
262
HEK-293 cells, transiently expressing PAR4-mCherry with PKCb1-GFP, showed 263 that activation of PAR4-mCherry with AYPGKF-NH2 causes a translocation of PKCb1-264 GFP from the cytosol to the plasma membrane ( Fig. 4A, B ). In contrast, HEK-293 cells 265 transiently expressing dRS-PAR4-mCherry with PKCb1-GFP showed that activation of After ruling out Gaq/11 as a potential signaling partner for PAR4-mediated 277 membrane blebs, we tested Gai recruitment as a potential regulator of these responses 278 through inhibition of Gai signaling with pertussis toxin. HEK-293 cells stably expressing 279 PAR4-YFP were incubated with pertussis toxin (100 nM) for 18 hrs prior to stimulating the 280 cells with 30 µM AYPGKF-NH2. We did not observe any reduction in the number of cells 281 that displayed blebbing when compared to cells incubated with vehicle control (saline), 282 76.3% +/-4.7 and 78.0% +/-3.4 respectively ( Fig. 5A-C) .
284
PAR4-mediated cell shape change is RhoA and ROCK dependent. 285 Since RhoA can be activated by a Gaq/11 and b-arrestin-1 dependent mechanism 286 following activation of the angiotensin II type 1 receptor (Barnes et al., 2005) show significantly fewer cells with blebs in response to agonist (22.8% +/-6.2) ( Fig. 6F ).
301
Taken together these data indicate that stimulation of PAR4-YFP elicits cell shape changes 302 that are blocked by blebbistatin and by the ROCK inhibitor GSK269962. Further, these 303 cell shape changes do not occur in cells that do not express RhoA protein, suggesting that 304 this signaling pathway is a RhoA and ROCK dependent pathway.
305
To confirm that these cellular responses can also be recapitulated by a physiological 306 PAR4 agonist, we tested the ability of thrombin to elicit similar cell shape changes. Since upregulated relating to cell-cell adhesion and GPCR signaling are consistent with our finding of b-arrestin-dependent membrane blebbing following PAR4 activation.
414
Discussion 415 We have demonstrated that activation of PAR4 with thrombin or the synthetic functions. PAR1 and PAR4 serve as the receptors for thrombin on human platelets, though 437 these receptors regulate different aspects of platelet activation (Coughlin, 1999; Kahn et al., 438 1999; Ma et al., 2005; Holinstat et al., 2006; Voss et al., 2007) . PAR4 is described as the In conclusion, we have uncovered a PAR4-mediated cellular response that is 502 independent of Gaq/11 coupling and occurs downstream of RhoA activation and b-arrestin 503 signaling. These data provide further evidence for pathway selective signaling responses 504 through PAR4 and guide future development of PAR4 targeting strategies. 
